With diversity being both a legal and popular factor in business, and with businesses facing a more diverse customer base, companies are making a conscious effort to develop and maintain a more culturally diverse workforce. Immigration, politics, new generations, women … Continue reading →

Cellceutix (OTCQB: CTIX) CEO Leo Ehrlich in September issued a fiscal year-end business statement recapping the company’s ability to usher its three unique compounds through various stages of clinical trials to successfully meet primary endpoints and drop anchors in several … Continue reading →

Cancer is the great scourge of our age. This year, 1.7 million Americans will find out they have the disease and some 600,000 will die from it. In total, approximately 40 percent of the population can expect to be diagnosed … Continue reading →

Neuralstem, Inc. (NASDAQ: CUR) is a biotechnology company whose patented technology allows for the production, on a commercial level, of a number of types of central nervous stem cells. These are in the development stage for the treatment of conditions … Continue reading →

A legal dispute with the European Patent Office over the European patent for its lead product candidate surprisingly presents a strong buying opportunity for clinical stage biopharmaceutical company Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR), according to an analysis report (http://dtn.fm/9UkRd) released … Continue reading →

Fortress Biotech, Inc. (NASDAQ: FBIO) is not putting all its eggs in one basket. This is a biopharmaceutical company with multiple revenue streams and a profuse product portfolio so diversified that Harry Markowitz, the father of modern portfolio theory, might … Continue reading →